On Jan. 15, HHS said it would update its guidelines to exempt physicians from the X waiver, a requirement mandated by Congress in 2000 that necessitates physicians receive a day’s training before they can prescribe buprenorphine, a drug that treats opioid addiction and chronic pain. Before he was elected, President Biden’s plan to end the opioid crisis supported this measure.
However, since President Biden took office, legal experts have warned the White House administration that HHS is not authorized to issue guidelines that allow physicians to eschew requirements Congress mandated, sources told the newspaper.
“Unfortunately, the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder announced by the Trump administration in its last days had significant legal and clinical concerns,” a draft announcement obtained by the Washington Post reads. “The Biden administration will not issue the guidelines previously announced.”
More articles on pharmacy:
Merck abandons its 2 COVID-19 vaccine candidates
CivicaRx to build drug manufacturing facility in Virginia
CVS says it’s completed first-round COVID-19 shots for skilled nursing facilities
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
